Since CARM1 depletion exacerbated sorafenib-induced ferroptosis, resulting in decreased cell viability, decreased cellular glutathione level, increased lipid peroxidation, and altered mitochondrial crista structure, CARM1 inhibitors may be used as novel ferroptosis inducers for the treatment of HCC [108]. This evidence concerns the gene CARM1 and hepatocellular carcinoma.